The latest news effecting cancer patients and oncology service delivery during the COVID-19 pandemic
Data from two large cancer centres in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care. The research, published in Annals of Oncology, shows that, compared to the immediate pre-pandemic period, there was a 46% decrease in new patient accruals, and a 24% decrease in newly activated trials between March and May 2020. In particular, a pronounced decrease in the numbers of new patients recruited to trials at Dana-Farber Cancer Institute (Boston, Massachusetts) and the Tisch Cancer Institute at Mount Sinai Medical School (New York) occurred in academically sponsored trials as opposed to…